-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
March 6, 2022 / Bio Valley BIOON / -- Many melanoma patients are treated with drugs called BRAF or MEK inhibitors, which specifically target mutated proteins produced in cancerous tumors.
Melanoma in skin biopsy under H&E staining
Image credit: Wikipedia/CC BY-SA 3.
The researchers say that because drugs such as BRAF and MEK inhibitors act quickly and effectively and increase patient survival, most patients experience disease relapse; to help address this, the researchers analyzed tissue Conducted spatial imaging analysis studies that may help them investigate the properties of the body's tumor and immune cells before and after patients develop resistance to BRAF and MEK inhibitors
When looking at drug-resistant tumors after treatment, the researchers found that melanoma cells with a specific biomarker, SOX10, may have increased significantly, suggesting that these cells may be resistant to therapy, and SOX10 is in the Precancerous cells may play a key role in the differentiation of cancerous melanoma cells.
Melanoma is the fifth most common type of cancer in the United States.
Image source: https:// present study highlights the fact that cancer development continues despite the proximity of immune cells to cancer cells, which may suggest that tumor cells resistant to therapy may be associated with an environment capable of inactivating immune cells.
Original source:
Yan, C.
